Madrigal Pharmaceuticals (MDGL) Leases (2019 - 2025)
Madrigal Pharmaceuticals (MDGL) has disclosed Leases for 7 consecutive years, with $4.9 million as the latest value for Q4 2025.
- On a quarterly basis, Leases rose 105.71% to $4.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.9 million, a 105.71% increase, with the full-year FY2025 number at $4.9 million, up 105.71% from a year prior.
- Leases was $4.9 million for Q4 2025 at Madrigal Pharmaceuticals, down from $5.4 million in the prior quarter.
- In the past five years, Leases ranged from a high of $5.9 million in Q2 2025 to a low of $411000.0 in Q2 2023.
- A 5-year average of $1.9 million and a median of $1.3 million in 2022 define the central range for Leases.
- Peak YoY movement for Leases: tumbled 61.12% in 2023, then soared 302.61% in 2025.
- Madrigal Pharmaceuticals' Leases stood at $797000.0 in 2021, then decreased by 24.47% to $602000.0 in 2022, then skyrocketed by 184.55% to $1.7 million in 2023, then soared by 40.16% to $2.4 million in 2024, then skyrocketed by 105.71% to $4.9 million in 2025.
- Per Business Quant, the three most recent readings for MDGL's Leases are $4.9 million (Q4 2025), $5.4 million (Q3 2025), and $5.9 million (Q2 2025).